Is Brooks Laboratories a Good Buy After Its Q1 FY27 Results?

The Brooks Laboratories share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Brooks Laboratories is a manufacturer of pharmaceutical formulations including IV fluids, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 23 crore, down 10.1% year on year, while the company reported a net loss of Rs 1.79 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Brooks Laboratories share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Brooks Laboratories share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Brooks Laboratories Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 23 crore	Rs 26 crore	-10.1%
EBITDA	Rs 2.04 crore	Rs 3.34 crore	-38.9%
Operating Margin	-5.1%	40.3%	NA
Profit Before Tax	-Rs 1.79 crore	Rs 9.58 crore	-118.7%
Net Profit / (Loss)	-Rs 1.79 crore	Rs 9.58 crore	-118.7%

Brooks Laboratories Q1 FY27 Performance Analysis

Check Brooks Laboratories Fundamentals on Univest Screener

Revenue declined 10.1% for the quarter, which was not offset by cost control, and the pharmaceutical formulations manufacturing business will need a stronger showing next quarter to reverse the trend.

The quarter's most important number is the swing to a net loss of Rs 1.79 crore, a reversal from the profit reported a year earlier. The revenue trend does not offset this either, and the Brooks Laboratories share price should be judged on when profitability is likely to return rather than on the topline trend.

On a sequential basis, revenue moved up 12.1% sequentially from Rs 21 crore in the March 2026 quarter and the net loss moved down 217.8% sequentially from Rs 1.52 crore in the prior quarter, giving a fuller picture of the trend behind the Brooks Laboratories share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Brooks Laboratories' revenue declined 10.1% year on year this quarter, taking the quarterly base to Rs 23 crore in a pharmaceutical formulations manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Brooks Laboratories share price.

Margin Movement

EBITDA fell to Rs 2.04 crore from Rs 3.34 crore, and operating margin slipped to -5.1% from 40.3% a year earlier, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.

Balance Sheet Position

Brooks Laboratories carries a low debt-to-equity ratio of 0.07, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

The stock trades at a PE of 41.3x, below the industry average of 51.2x, which is worth factoring into any read of whether the Brooks Laboratories share price is expensive or reasonably priced.

Dividend Details

No interim dividend was declared alongside Brooks Laboratories' Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Brooks Laboratories share price for income should watch the company's announcements around its next annual results for any dividend decision.

Brooks Laboratories Share Price Outlook for FY27

Brooks Laboratories' path back to profitability is the central question for FY27. Revenue growth is a positive signal, but until the company demonstrates it can convert that growth into profit again, the Brooks Laboratories share price is likely to stay sensitive to every quarterly update.

Investors should track cost trends and any management commentary on when profitability is expected to normalise, since that timeline will likely matter more to the Brooks Laboratories share price than revenue growth alone.

Brooks Laboratories Stock Performance

Download the Univest iOS App or Univest Android App to track Brooks Laboratories' live share price and get daily stock updates.

The Brooks Laboratories share price was trading around Rs 64 as results season played out in late August 2026, roughly 61.0% below its 52-week high of Rs 164 and well above its 52-week low of Rs 36.

The Brooks Laboratories share price has likely already absorbed some of this quarter's disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 4.80% and a book value of around Rs 41 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Profitability Risk

The quarter's profit trend is the clearest risk here. Until Brooks Laboratories shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical formulations manufacturing business, Brooks Laboratories' results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Brooks Laboratories share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Brooks Laboratories' swing to a net loss of Rs 1.79 crore in Q1 FY27 is the standout number from this result, with revenue also under pressure. The Brooks Laboratories share price is best approached cautiously until the company shows a credible path back to profitability, and this quarter alone does not make a strong case to buy.

Frequently Asked Questions on Brooks Laboratories Q1 FY27 Results

What were Brooks Laboratories' Q1 FY27 results?

Ans. Brooks Laboratories reported Q1 FY27 revenue of Rs 23 crore, down 10.1% year on year, with a net loss of Rs 1.79 crore.

Is Brooks Laboratories a good buy after its Q1 FY27 results?

Ans. Brooks Laboratories' profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Brooks Laboratories share price today?

Ans. The Brooks Laboratories share price was trading around Rs 64 in late August 2026, about 61.0% below its 52-week high of Rs 164 and well above its 52-week low of Rs 36.

What is Brooks Laboratories' revenue and profit for Q1 FY27?

Ans. Brooks Laboratories reported revenue of Rs 23 crore and a net loss of Rs 1.79 crore for the quarter ended June 30, 2026.

Did Brooks Laboratories declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Brooks Laboratories' Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

What is Brooks Laboratories' PE ratio and is it expensive?

Ans. The Brooks Laboratories share price trades at a trailing PE of 41.3x, against an industry average of 51.2x. Investors should compare this with the company's growth rate before judging value.

What are the key risks for Brooks Laboratories investors right now?

Ans. The quarter's profit trend is the clearest risk here. Until Brooks Laboratories shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Brooks Laboratories' promoter shareholding?

Ans. Promoter shareholding data for Brooks Laboratories was not fully available for this quarter and should be checked on the company's official filings.